Authors
Lin JD, Liou MJ,
Chao TC, Weng HF,
Ho
Seabold JE, Gurll N,
Schurrer ME, Aktay
R, Kirchner
McDougallFranklyn JA,
Maisonneuve P,
Sheppard M,
Betteridge J, Boyle

Title
JournalYear
Prognostic variables of papillary Endocr
and follicular thyroid carcinoma Relat
1999
Cancerpatients with lymph nodeComparison of 99mTcmethoxyisobutyl isonitrile and J Nucl Med 1999
201Tl scintigraphy for detection
Cancer deaths after 131I
Nucl Med1999
Cancer incidence and mortality
after radioiodine treatment forLancet1999
hyperthyroidism: a populationbased cohort study.
Ablation of the thyroid remnant Clin
Doi SA, Woodhouse2000
and 131I dose in differentiated Endocrinol
Curr Treat
Kebebew E, Clark
Medullary thyroid cancer.
2000
Options
Curr Treat
Yim JH, Doherty
Papillary thyroid cancer.
2000
Options
Differentiated thyroid cancer: World J
Kebebew E, Clark
2000"complete" rational approach. Surg
Griffiths PA, Jones Radiation protection
GP, Marshall C,
consequences of the care of a Br J Radiol 2000
Powleyterminally ill patient having
Shingu K, Kobayashi The likely transformation ofS, Yokoyama S,
papillary thyroid carcinoma into
Surg Today 2000
Fujimori M, Asanuma anaplastic carcinoma during
K, Ito KI, Hama Y,
postoperative radioactive
Maruyama M, Kusama iodine-131 therapy: report of a
Differentiated thyroid cancer:
La Quaglia MP, Black clinical characteristics,
T, Holcomb GW 3rd, treatment, and outcome in
J Pediatr
patients under 21 years of age
2000
Sklar C, Azizkhan
Surg
who present with distant
RG, Haase GM,
metastases. A report from theNewmanSurgical Discipline Committee
Pittas AG, Adler M, Bone metastases from thyroid
Fazzari M, Tickoo S, carcinoma: clinicalThyroid
2000
Rosai J, Larson SM, characteristics and prognostic
Robbinsvariables in one hundred fortySautter-Bihl ML,
Differentiated thyroid cancer:
Strahlenther
Raub J, Hetzelprognostic factors and
2001
Onkol
Sesterheim M, Heinze influence of treatment on the
Chas J, Kowalczyk A, [Environmental radiation
Siekierzynski M,
exposure of a thyroid cancer
Wiad Lek
2001
Dziuk E, Janiak
patient resulting from adjuvant
Dequanter D,Ann[Isolated pelvic metastasis of
Abdoulaye D,
Endocrinol 2001
thyroid cancer].
Lothaire P, Gebhart(Paris)Hadjieva
Scoring patients' risk inOnkologie
2001
Tutal E, Tutuncu NB, Unusual case of metastatic
EndocrAkcaer N, Bilezikci B, thyroid nodule: nonpalpable
2001
Pract
Guvener N, Arican
breast mass as origin.
Long-term comparative cancer
J Insur Med 2001
mortality after use of radioSinger
iodine in the treatment ofClinical features ofNucl MedBal CS, Padhy AK,
differentiated thyroid carcinoma
2001
CommunKumar
in children and adolescents

Volume Pages
6(1)109-1540(9)1434-40

20(5)

407-9

353(91702111-552(6)765-731(4)359-671(4)329-3824(8)942-5173(875) 1209-1230(10)

910-3

35(6)

955-9;
discussion
960

10(3)

261-8

177(3)

125-3154 Suppl 312-20
62(6)

521-4

24(6)

561-8

7(5)

379-8233(2)138-42

22(8)

881-7

Mukherjee JJ,
Kaltsas GA, Islam N,
Plowman PN, Foley
R, Hikmat J, Britton
KE, Jenkins PJ,
Chew SL, Monson
JP, Besser GM,
Al-Balawi IA, Meir
HM, Yousef MK,
Nayel HA, AlThompson LD,
Wieneke JA, Paal E,
Frommelt RA, Adair
CF, Heffess

Treatment of metastatic
carcinoid tumours,Clinphaeochromocytoma,
Endocrinol 2001
paraganglioma and medullarycarcinoma of the thyroid with (Oxf)(131)I-metaiodobenzylguanidine [(131)IDifferentiated thyroid
carcinoma referred for
Saudi Med J 2001
radioiodine therapy.
A clinicopathologic study ofminimally invasive follicular
Cancer
2001
carcinoma of the thyroid glandwith a review of the English[The initial treatment of
Ned
Smit
2002
patients with differentiatedTijdschr
Patel A, Jhiang S,
Differentiated thyroid
Dogra S, Terrell R,
carcinoma that express
Powers PA, Fenton sodium-iodide symporter have Pediatr Res 2002
C, Dinauer CA, Tuttle a lower risk of recurrence for
RM, Francis
children and adolescents.
Grigsby PW, Gal-or Childhood and adolescent
Cancer
2002
A, Michalski JM,
thyroid carcinoma.
Oueslati Z, Aloui M,
Rev
Gritli S, Touati S, el- [Thyroid papillary
Laryngol
May A, Gamoudi A, microcarcinoma. Salah Azaiz
2002
Otol Rhinol
Institute experience].
Ben-Slimene F,(Bord)
LadghamBeasley NJ, Lee J,
Impact of nodal metastases on ArchEski S, Walfish P,
prognosis in patients with well- Otolaryngol 2002
Witterick I, Freeman differentiated thyroid cancer.
Head Neck
Well-differentiated thyroid
J Am Coll
Lee YM, Lo CY, Lam
carcinoma in Hong Kong
2002
Surg
KY, Wan KY, Tam
Chinese patients under 21
Gemsenjager E, Heitz [Differentiated thyroid
carcinoma. Surgery andChirurg
2002
PU, Martina B,
Schweizer
significance of lymph node
Zettinig G, Fueger
Long-term follow-up ofClin
BJ, Passler C,
patients with bone metastases
Endocrinol 2002
Kaserer K, Pirich C, from differentiated thyroid(Oxf)
Dudczak R, Niederle carcinoma -- surgery or
Chow SM, Law SC,
Papillary thyroid carcinoma:
Mendenhall WM, Au
Int J Radiat
prognostic factors and the role
SK, Chan PT, Leung
Oncol Biol 2002of radioiodine and external
TW, Tong CC, Wong
Phys
radiotherapy.
IS, LauGerard SK, Park
131I dosimetry and thyroid
J Nucl Med 2003
Kumar A, Bal
Differentiated thyroid cancer. Indian J
2003
Gow KW, Lensing S, Thyroid carcinoma presenting in
Hill DA, Krasin MJ,
childhood or after treatment of
J Pediatr
McCarville MB, Raichildhood malignancies: An
2003
Surg
SN, Zacher M, Spunt institutional experience andSL, Strickland DK,
review of the literature.
Eichhorn W, Tabler H, Prognostic factors determining
Lippold R, Lochmann long-term survival in wellThyroid
2003
M, Schreckenberger differentiated thyroid cancer:
M, Bartenstein
an analysis of four hundred

55(1)

47-60

22(6)

497-50391(3)505-24146(10) 454-752(5)737-44

95(4)

724-9

123(1)

39-42

128(7)

825-8

194(6)

711-6

73(1)

38-43; discussion 43-5

56(3)377-8252(3)784-9544(12)
70(9)2039-40; author reply
707-1338(11)

1574-80

13(10)

949-58Rubino C, deVathaire F, Dottorini
ME, Hall P, Schvartz Second primary malignancies in
Br J Cancer 2003
thyroid cancer patients.
C, Couette JE,
Dondon MG, Abbas
MT, Langlois C,
Radioiodine therapy in patients Eur J Nucl
2003
with pulmonary metastases of Med Mol
Reiners
thyroid cancer: when to treat, Imaging
Besic N, VidergarThe role of radioactive iodine in
Kralj B, Frkovicthe treatment of Hurthle cell
Thyroid
2003
Grazio S, Movrincarcinoma of the thyroid.
Stanovnik T,
Powers PA, Dinauer Tumor size and extent of
J Pediatr
CA, Tuttle RM, Robie disease at diagnosis predict the
Endocrinol 2003
DK, McClellan DR,
response to initial therapy for
MetabFrancispapillary thyroid carcinoma in
Gotthardt M, Nowack Negative correlation between
Eur J Nucl
M, Behe MP,
therapeutic success in
Med Mol
2003
Schipper ML,
radioiodine therapy and TcTUs:
Imaging
Schlieck A, Hoffken are TcTUs-adapted dose
Karam M,
Influence of diagnostic andGianoukakis A,
Nucl Medtherapeutic doses on thyroid
2003
Feustel PJ, Cheema
Communremnant ablation rates.
A, Postal ES, Cooper
Dorn R, Kopp J, Vogt Dosimetry-guided radioactive
H, Heidenreich P,
iodine treatment in patients
J Nucl Med 2003
Carroll RG, Gulec
with metastatic differentiatedKim TH, Yang DS,
Value of external irradiation for Int J Radiat
Jung KY, Kim CY,
locally advanced papillary
Oncol Biol 2003
Choi
thyroid cancer.
Phys
Radiation protection
Australas
Woodings
2004
recommendations for I-131
Phys Eng
thyrotoxicosis, thyroid cancer Sci Med
Mallick UK,
Current issues in the
Nucl Med2004
Charalambous
management of differentiated Commun
Sawka AM,
Clinical review 170: A
Thephamongkhol K, systematic review andJ ClinBrouwers M, Thabane metaanalysis of the
Endocrinol 2004
L, Browman G,
effectiveness of radioactive
Metab
Gerstein
iodine remnant ablation for
Souza Rosario PW,
Post I-131 therapy scanning in
Barroso AL, Rezende
patients with thyroid carcinoma Clin Nucl
LL, Padrao EL,
2004
metastases: an unnecessaryMed
Fagundes TA, Pennacost or a relevant contribution?
GC, Purischde Keizer B,
Bone marrow dosimetry and
Hoekstra A,
safety of high 131I activities
Konijnenberg MW, de given after recombinant human J Nucl Med 2004
Vos F, Lambert B,
thyroid-stimulating hormone tovan Rijk PP, Lips CJ, treat metastatic differentiatedHaq MS, McCready Treatment of advanced
Nucl Med
2004
RV, Harmer
differentiated thyroid carcinoma Commun
Influence of 131I diagnostic
Hu YH, Wang PW,
dose on subsequent ablation in
Wang ST, Lee CH,
Nucl Medpatients with differentiated2004
Chen HY, Chou FF,
Communthyroid carcinoma: discrepancy
Huang YE, Huang
between the presence of89(9)1638-4430(7)939-4213(6)577-8416(5)693-70230(8)1165-824(5)489-95

44(3)

451-6

55(4)

1006-1227(3)118-2825(9)873-8189(8)3668-76

29(12)

795-8

45(9)

1549-5425(8)799-805

25(8)

793-7

Stokkel MP,
Verkooijen RB, Smit

Indium-111 octreotide
Eur J Nucl
scintigraphy for the detection Med Molof non-functioning metastases Imaging

2004 31(7)Berthe E, HenryAmar M, Michels JJ,
Risk of second primary cancer Eur J Nucl
Rame JP, Berthet P,
following differentiated thyroid Med Mol
2004
Babin E, Icard P,
cancer.
Imaging
Samama G,
Galateau-Salle F,
Are there disadvantages in
Clin
Salvatori M, Perotti
administering 131I ablation
Endocrinol 2004
G, Rufini V, Maussier
therapy in patients with
(Oxf)
ML, Dottorini
differentiated thyroid carcinoma[Poorly differentiated thyroid
Ai Zheng
2004
Liu WS, Qi YF, Tangfollicular carcinoma - a clinical
Kita T, Yokoyama K, Multifactorial analysis on the
Higuchi T, Kinuya S, short-term side effects
Ann Nucl
2004
Taki J, Nakajima K, occurring within 96 hours after Med
Michigishi T, Tonami radioiodine-131 therapy for
Causeret S, Lifante [Differentiated thyroid
JC, Borson-Chazot carcinoma in children and
Ann Chir
2004
F, Varcus F, Berger adolescents: therapeutic
N, Peix
strategy according to clinic
Palme CE, Waseem Management and outcome ofArch
Z, Raza SN, Eski S, recurrent well-differentiatedOtolaryngol 2004
Head Neck
Walfish P, Freeman thyroid carcinoma.
Lin JD, Chao TC,
Follicular thyroid carcinomas
Endocr J
2004
Hsueh
with lung metastases: a 23-year
Chow SM, Law SC, Differentiated thyroid
Pediatr
Mendenhall WM, Au carcinoma in childhood and
Blood
2004
SK, Yau S, Mang O, adolescence-clinical course andCancerrole of radioiodine.
Lau
Medvedec
Thyroid stunning in vivo and in Nucl Med
2005
Is empiric 131I therapy justified
Ma C, Xie J, Kuang for patients with positive
J Nucl Med 2005
thyroglobulin and negative 131I
Robbins RJ,
The evolving role of (131)I for
J Nucl Med 2005
Schlumberger
the treatment of differentiatedRubino C, Adjadj E,
Doyon F, Shamsaldin
A, Abbas TM, Caillou Radiation exposure and familial
aggregation of cancers as risk Int J Radiat
B, Colonna M,
Cecarreli C, Schvartz factors for colorectal cancer
Oncol Biol 2005
C, Bardet S, Langlois after radioiodine treatment for Phys
thyroid carcinoma.
C, Ricard M,
Schlumberger M, deVathaire
Popova L,
Cytokinesis-block micronucleus
Hell J Nucl
Hadjidekova V,
test in patients undergoing
2005
Med
Hadjieva T, Agova S, radioiodine therapy for
Violot D, M'Kacher R, Evidence of increased
Eur J Nucl
Adjadj E, Dossou J, chromosomal abnormalities in Med Mol
2005
de Vathaire F,
French Polynesian thyroid
Imaging
Pazaitou-Panayiotou Thyroid carcinoma in children
K, Kaprara A,
and adolescents: presentation,
Hormones
Boudina M, Georgiou clinical course, and outcome of2005(Athens)
E, Drimonitis A,
therapy in 23 children and
Vainas I, Raptou E,
adolescents in Northern

950-7

31(5)

685-9161(6)704-1023(9)1081-4

18(4)

345-9

129(6-7) 359-64

130(7)

819-2451(2)219-2542(2)176-83

26(8)

731-5

46(7)

1164-70

46 Suppl 28S-37S

62(4)1084-9

8(1)

54-7

32(2)

174-9

4(4)

213-20Iuchi Y, Sato K,[Acute lymphoblastic leukemia
Jimbo J, Inamura J,
with t(4;11)(q21;q23) after
RinshoShindo M, Ikuta K,
2005
iodine-131 treatment for
KetsuekiShinzaki H, Ohnishi K,
thyroid cancer].
Watanabe S,
Podnos YD, Smith D, Radioactive iodine offers
Surgery
2005
Wagman LD,
survival improvement in
Rosa Pelizzo M,
Toniato A, Boschin Locally advanced differentiatedIM, Piotto A,
thyroid carcinoma: a 35-year
Nucl Med
2005
Bernante P, Pagetta mono-institutional experience Commun
C, Palazzi M, Mariain 280 patients.
Guolo A, Preo P,
Williams CE,
Management of the helplessNucl Med2005
Woodward
patient after radioiodine
CommunAlzahrani AS,
Long-term course andMohamed G, Al
predictive factors of elevatedJ Endocrinol
Shammary A,
serum thyroglobulin and2005
InvestAldasouqi S, Abdal
negative diagnostic radioiodine
Salam S, Shoukri
whole body scan in
Leboulleux S, Rubino Prognostic factors for
C, Baudin E, Caillou persistent or recurrent disease J Clin
B, Hartl DM, Bidart of papillary thyroid carcinoma Endocrinol 2005
JM, Travagli JP,
with neck lymph nodeMetabmetastases and/or tumor
Schlumberger
Heymann RS, Brent Anaplastic thyroid carcinoma
Endocr2005
GA, Hershmanwith thyrotoxicosis andPract
Kozak OV, Sukach
Hierarchy of treatment
GG, Korchinskaya OI, variables affecting outcome of
Exp Oncol 2005
Trembach AM,
131I therapy in thyroid cancer
Turicina VL, Voit
patients with lung metastases.
Rosario PW, Barroso Outcome of ablation of thyroid
Ann Nucl
AL, Rezende LL,
remnants with 100 mCi (3.7
2005
Med
Padrao EL, Fagundes GBq) iodine-131 in patients
TA, Reis JS, Purisch with thyroid cancer.
Worth AJ, Zuber RM, Radioiodide (131I) therapy forAust Vet J 2005
Hocking
the treatment of canine thyroid
Hod N, Hagag P,
Differentiated thyroid
Clin Nucl
Baumer M, Sandbank carcinoma in children and2005
MedJ, Horne
young adults: evaluation of[Controversies in the follow-up
Rev Esp
Abos Olivares MD,
and management of well2005
Med Nucl
Pesquera Gonzalez
differentiated thyroid cancer.
A model for predicting
J Am Colloutcomes in patients with
Yildirim
2005
Surg
differentiated thyroid cancer
Panzegrau B, Gordon Outpatient therapeutic 131I for J Nucl Med
2005
L, Goudy
thyroid cancer.
Technol
Rosario PW, Barroso
Ablative treatment of thyroid
AL, Rezende LL,
Nucl Medcancer with high doses of 131I
2005
Padrao EL, Borges
Communwithout pre-therapy scanning.
MA, Fagundes TA,
Risk of parathyroid adenomas in
Acta Oncol 2006
Rasmuson T, Tavelinpatients with thyrotoxicosis
Willegaignon J, Stabin Evaluation of the potential
MG, Guimaraes MI,
absorbed doses from patients
Health Phys 2006
Malvestiti LF,
based on whole-body 131I
Sapienza MT, Maroni clearance in thyroid cancer

46(11)

1202-7

138(6)

1072-6; discussion 107

26(11)

965-8

26(10)

925-8

28(6)

540-6

90(10)

5723-9

11(4)

281-4

27(2)

150-5

19(3)

247-5083(4)208-1430(6)387-9024(3)207-15200(3)

378-92

33(1)

28-30

26(2)

129-3245(8)1059-61

91(2)

123-7

Jentzen W, Schneider Relationship between
E, Freudenberg L,
cumulative radiation dose andNucl Med
Eising EG, Gorges R, salivary gland uptake
2006
CommunMuller SP, Brandau associated with radioiodine
W, Bockischtherapy of thyroid cancer.
Sioka C, Kouraklis G,
Menstrual cycle disorders after
Zafirakis A, Manetou
Fertil Steril 2006
therapy with iodine-131.
A, Dimakopoulos
Chatal JF, Campion Survival improvement in
L, Kraeber-Bodere F, patients with medullary thyroid
Bardet S, Vuillez JP, carcinoma who undergo
J Clin Oncol 2006
Charbonnel B,
pretargeted antiRohmer V, Chang
carcinoembryonic-antigen
CH, Sharkey RM,
radioimmunotherapy: aGoldenberg DM,
collaborative study with the
Kraeber-Bodere F,
Targeting, toxicity, and efficacy
Rousseau C, Bodetof 2-step, pretargeted
Milin C, Ferrer L,
radioimmunotherapy using a
Faivre-Chauvet A,
chimeric bispecific antibody and J Nucl Med 2006
Campion L, Vuillez
131I-labeled bivalent hapten in
JP, Devillers A,a phase I optimization clinical
Chang CH,
trial.
Goldenberg DM,
Brain metastases from papillary J
2006
Yousuf K, Archibald
adenocarcinoma of the thyroid. Otolaryngol
Contralateral papillary thyroid
Grigsby PW, Reddy
cancer at completion
Surgery
2006
RM, Moley JF, Hall
thyroidectomy has no impact
Local and regional control in
Chow SM, Yau S,
Endocrpatients with papillary thyroid
Kwan CK, Poon PC,
Relat
2006
carcinoma: specific indications
Law
Cancerof external radiotherapy andCappelli C, Pirola I,
Braga M, De Martino Prognostic factors in wellE, Morassi ML,
differentiated thyroid carcinoma
Ann Ital Chir 2006
Gandossi E, Mattanza in patients treated and followed
C, Balzano R,
in the same institution.
Castellano M, Rosei
Verkooijen RB, Smit The incidence of second
Eur J
JW, Romijn JA,
primary tumors in thyroid
2006
Endocrinol
Stokkelcancer patients is increased,
Selective use of radioactive
J Surgiodine in the postoperative
Hay
2006
Oncol
management of patients with
Recombinant human
Robbins RJ, Driedger thyrotropin-assisted radioiodine
Thyroid2006
therapy for patients with
A, Magner
metastatic thyroid cancer who
Timing and potential role ofBrzozowska M,
diagnostic I-123 scintigraphy in Clin Nucl
2006
Roach
Med
assessing radioiodine breast
uptake before ablation in
Arias F, Vives R,
Cutaneous nodes in a patient Clin Transl
2006
Gomez-Dorronsoro with advanced papillary
Oncol
Bhattacharyya N,
Risk of second primary
Ann Otol2006
Chien
malignancy after radioactive
Rhinol27(8)669-76

86(3)

625-8

24(11)

1705-1147(2)247-5535(6)366-72140(6)

1043-7; discussion 10413(4)1159-7277(2)107-13

155(6)

801-6

94(8)

692-700

16(11)

1121-3031(11)

683-7

8(9)

692-3

115(8)

607-10Saghari M,
Efficacy of radioiodine therapy
Gholamrezanezhad A, in the treatment of elevatedMirpour S, Eftekhari serum thyroglobulin in patients Nucl Med
2006
CommunM, Takavar A, Fard- with differentiated thyroid
Esfahani A, Fallahi B, carcinoma and negative wholeBeiki
body iodine scan.
Benbassat CA,
Clinicopathological
World J
Mechlis-Frish S,
characteristics and long-term
2006
Surg
Hirschoutcome in patients withLo CY, Chan WF,
Papillary microcarcinoma: isWorld J
2006
Lang BH, Lam KY,
there any difference between Surg
Segal K, Shpitzer T, Invasive well-differentiatedOtolaryngol
Hazan A, Bachar G, thyroid carcinoma: effect ofHead Neck 2006
Marshak G,
Surg
treatment modalities on
Keum KC, Suh YG,
The role of postoperative
Koom WS, Cho JH,
external-beam radiotherapy in Int J Radiat
Shim SJ, Lee CG,
the management of patients
Oncol Biol 2006
Park CS, Chung WY, with papillary thyroid cancer
PhysKim
invading the trachea.
Chuang SC, HashibeRadiotherapy for primaryM, Yu GP, Le AD,
thyroid cancer as a risk factor Cancer Lett 2006
Cao W, Hurwitz EL,
for second primary cancers.
Rao JY, Neugut AI,
Walter MA, Turtschi The dental safety profile of
CP, Schindler C,
high-dose radioiodine therapy
J Nucl Med 2007
Minnig P, Mullerfor thyroid cancer: long-term
results of a longitudinal cohort
Brand J, Muller
Freudenberg LS,
124-iodine positron emission
Exp Clin
Jentzen W, Marlowe tomography/computed
Endocrinol 2007
RJ, Koska WW,
tomography dosimetry in
Diabetes
Luster M, Bockisch pediatric patients with
Sawka AM, Rotstein
L, Brierley JD, Tsang Regional differences in opinions
RW, Thabane L, Gafni on adjuvant radioactive iodine
treatment of thyroid carcinoma Thyroid
A, Straus S,
2007
within Canada and the United
Kamalanathan S,
States.
Zhao B, Goldstein
DP, Rambaldini G,
Lin JD, Chao TC,
Operative strategy for follicular
Chen ST, Huang YY, thyroid cancer in risk groups
Surg Oncol 2007
Liou MJ, Hsueh
stratified by pTNM staging.
Podnos YD, Smith
Survival in patients withJ Surg2007
DD, Wagman LD,
papillary thyroid cancer is not Oncol
Giovanella L, Ceriani Preoperative undetectable
Clin
L, Ghelfo A, Maffioli serum thyroglobulin in
Endocrinol 2007
M, Kellerdifferentiated thyroid(Oxf)
Saint-Vil D, Emran
Cumulative doses of adjunct
J Pediatr
MA, Lambert R, Alos 131I treatment depend on
2007
Surg
N, Turpin S, Huot
location of residual thyroid
Kucuk NO, Tari P,
Treatment for microcarcinoma Clin Nucl
2007
Tokmak E, Arasof the thyroid--clinicalMed
Metso S, Auvinen A, Increased cancer incidence
Huhtala H, Salmi J, after radioiodine treatment for Cancer
2007
Oksala H, Jaatinen
hyperthyroidism.
Metso S, Jaatinen P, Increased cardiovascular andJ ClinHuhtala H, Auvinen cancer mortality after
Endocrinol 2007
A, Oksala H, Salmi
radioiodine treatment for
Metab

27(7)

567-7230(6)1088-9530(5)759-66134(5)

819-2265(2)474-80238(1)

42-52

48(10)

1620-5115(10) 690-3

17(12)

1235-4216(2)107-13

96(1)

3-7

67(4)

547-51

42(5)

853-6

32(4)

279-81109(10) 1972-992(6)2190-6

Hindie E, ZanottiShould 'low-risk' thyroid cancer
Clin
Fregonara P, Duron patients with residual
Endocrinol 2007
F, Keller I, Bouchard thyroglobulin be re-treated with
(Oxf)
P, Devaux
iodine 131?
Reiners C, Demidchik Thyroid cancer in infants andMinerva2008
YE, Drozd VM, Biko adolescents after Chernobyl.
Endocrinol
Page C, Biet A,[Management of the papillary
J
2008
Zaatar R, Charlet L, microcarcinoma of the thyroid Otolaryngol
Azrif M, Slevin NJ,
Patterns of relapse following
RadiotherSykes AJ, Swindell R, radiotherapy for differentiated
2008
Oncol
Yap
thyroid cancer: implication for
Lin JD, Lin KJ, Chao Therapeutic outcomes ofRadiother2008
TC, Hseuh C, Tsang papillary thyroid carcinomas
Oncol
Brown AP, Chen J, The risk of second primary
J ClinHitchcock YJ, Szabo malignancies up to three
Endocrinol 2008
A, Shrieve DC, Tward decades after the treatment of Metab
Schlumberger MJ,
The low utility of pretherapy
Thyroid2009
Paciniscans in thyroid cancer
Weighing shadows: can metaSchneider AB, Viana
Thyroid2009
analysis help define the riskMA, Ronbenefit ratio of RAI treatment
Influence of previous radiation Arch
Seaberg RM, Eski S,
exposure on pathologic features Otolaryngol 2009
Freemanand clinical outcome in patients Head Neck
Sawka AM, Thabane Second primary malignancy risk
L, Parlea L, Ibrahim- after radioactive iodine
2009
treatment for thyroid cancer: a Thyroid
Zada I, Tsang RW,
Brierley JD, Straus systematic review and metaS, Ezzat S, Goldstein analysis.
Therapeutic strategy of
Minerva
Riemann B, Schober
2009
papillary microcarcinoma of the Endocrinol
Biermann M, Pixberg Clinical outcomes of adjuvant
M, Riemann B,
external-beam radiotherapy for
Nuklearmedi
Schuck A, Heinecke differentiated thyroid cancer 2009zin
A, Schmid KW, Willich results after 874 patient-years
N, Dralle H, Schober of follow-up in the MSDS-trial.
Chianelli M, Todino V, Low-activity (2.0 GBq; 54 mCi)
Graziano FM, Panunzi radioiodine post-surgical
Eur J
2009
C, Pace D, Guglielmi remnant ablation in thyroid
Endocrinol
R, Signore A, Papini cancer: comparison between
Duque-Fisher CS,
Acta
Casiano R, Velez[Metastasis to the sinonasal
Otorrinolarin 2009
Hoyos A, Londono- region].
gol Esp
Bustamente
Maatouk J, Barklow Anaplastic thyroid carcinoma
Acta Cytol 2009
TA, Zakaria W, Alarising in long-standing
Abbadi
multinodular goiter following
Luster M,
Handkiewicz-Junak Recombinant thyrotropin use in
J ClinD, Grossi A, Zacharin children and adolescents with
Endocrinol 2009
M, Taieb D, Cruz O, differentiated thyroid cancer: aMetab
Hitzel A, Casas JA, multicenter retrospective study.
Mader U, Dottorini
Rios A, ManuelRodriguez J,[Distant metastases as the
Endocrinol
Balsalobre MD,
initial manifestation of follicular
2009
Nutr
Febrero B, Tebar J, thyroid carcinoma].
Parrilla66(3)329-3433(4)381-9537(5)649-5689(1)105-1389(1)97-10493(2)504-15

19(8)

815-6

19(5)

435-6

135(4)

355-9

19(5)

451-7

34(1)

81-7

48(3)

89-98; quiz N15

160(3)

431-6

60(6)

428-31

53(5)

581-3

94(10)

3948-53

56(4)

213-4

Chen PV, Osborne R, Adjuvant external-beam
Ear Nose
Ahn E, Avitia S,
radiotherapy in patients with
2009
Throat J
Juillard
high-risk well-differentiatedMihailovic JM,
Metastatic differentiatedStefanovic LJ,
thyroid carcinoma: clinical
Nucl Med2009
Malesevic MD, Erak management and outcome ofCommunMD, Tesanovic
disease in patients with initial
Leenhardt[Management of thyroid
J Radiol2009
A vision for the surgical
J Clinmanagement of papillary thyroid
Mazzaferri
Endocrinol 2009carcinoma: extensive lymphMetabnode compartmental
Arora N, Turbendian
Papillary thyroid carcinoma andHK, Kato MA, Moo
microcarcinoma: is there a need Thyroid
2009
TA, Zarnegar R,
to distinguish the two?
Fahey TJ 3
Gorgone S, Campenni
A, Calbo E,[Differentiated thyroid cancers]. G Chir
2009
Catalfamo A,
Sciglitano P, Sofia L,
Niceta M, Borzi R,
Naing S, Collins BJ, Clinical behavior of radiationThyroid
2009
Schneiderinduced thyroid cancer: factors
Miccoli P, Pinchera Surgical treatment of low- andJ ClinA, Materazzi G,intermediate-risk papillary
Endocrinol 2009
Biagini A, Berti P,
thyroid cancer with minimally
MetabFaviana P, Molinaro invasive video-assisted
thyroidectomy.
E, Viola D, Elisei
Lazar L, Lebenthal Y, Differentiated thyroid
Steinmetz A,
carcinoma in pediatric patients:
J Pediatr
2009
Yackobovitch-Gavan comparison of presentation andcourse between pre-pubertal
M, Phillip
Terezakis SA, Lee
Role of external beamKS, Ghossein RA,
radiotherapy in patients withInt J Radiat
Rivera M, Tuttle RM, advanced or recurrent
Oncol Biol 2009
Wolden SL, Zelefsky nonanaplastic thyroid cancer:
Phys
MJ, Wong RJ, Patel Memorial Sloan-kettering
Cancer Center experience.
SG, Pfister DG,
Mendelsohn AH,
Surgery for papillary thyroidArch
Elashoff DA,
carcinoma: is lobectomy
Otolaryngol 2010
Abemayor E, St John enough?
Head Neck
Sacks W, Fung CH,
The effectiveness of
Chang JT, Waxman radioactive iodine for treatment Thyroid
2010
A, Braunsteinof low-risk thyroid cancer: a
Outcomes of children andPawelczak M, David
adolescents with wellThyroid
2010
R, Franklin B, Kessler
differentiated thyroid carcinoma
M, Lam L, Shahand pulmonary metastases
Medullary thyroid cancer: are
Panigrahi B, Roman
Ann Surg
practice patterns in the United
2010
SA, Sosa
Oncol
States discordant from

88(7)

E01

30(7)

558-6490(3 Pt 2354-61
94(4)1086-8

19(5)

473-7

30(1-2) 26-9

19(5)479-8594(5)1618-22154(5)

708-1473(3)795-801

136(11) 1055-61
20(11)

1235-45

20(10)

1095-10117(6)1490-8

Bible KC, Suman VJ,
Molina JR, Smallridge
RC, Maples WJ,
Efficacy of pazopanib in
Menefee ME, Rubin J,
progressive, radioiodineSideras K, Morris JC
refractory, metastatic
Lancet3rd, McIver B, Burton
differentiated thyroid cancers: Oncol
JK, Webster KP,
results of a phase 2 consortium
Bieber C, Traynor
study.
AM, Flynn PJ, Goh
BC, Tang H, Ivy SP,
Erlichman
Current and emerging
Ther Clin
Abraham P, Acharya
treatment options for Graves' Risk Manag
Sugitani I, Toda K,
Three distinctly different kinds
World J
Yamada K,of papillary thyroid
Surg
Yamamoto N, Ikenaga microcarcinoma should be
Listewnik MH,
The occurrence of malignant
Birkenfeld B, Chosia
thyroid lesions in patients after Endokrynol
M, Elbl B,
radioiodine treatment due toPol
Niedzialkowska K,
benign thyroid diseases.
Sawrymowicz
Reverter JL, Colome [Comparative study of historical
E, Halperin I, Julian T, series of differentiated thyroid
Endocrinol
Diaz G, Mora M,
carcinoma in two tertiary
Nutr
Sanmarti A, Puighospitals in Spain versus North
American series].
DomingoBasbug M, Ozgun MT, Prenatal diagnosis of fetal
J ClinMurat N, Batukan C, hypothyroidism after maternal
UltrasoundOzcelik B, Kurtoglu radioactive iodine exposure
Mulazimoglu M, Edis The evaluation of the external
Radiat Prot
N, Tamam MO,
dose measurement of the
Dosimetry
Uyanik E, Ozpacaci patients treated with
Baranauskas Z,[Outcomes of long-term
Medicina
Valuckas KP,
combined treatment in follicular(Kaunas)Tiskevicius
thyroid carcinoma].
Kushchayev S,
Percutaneous vertebroplasty
Kushchayeva Y,
for thyroid cancer metastases Thyroid
Theodore N, Preulto the spine.
MC, Clark
Silva F, Laguna R,
Pediatric thyroid cancer withJ Pediatr
Nieves-Rivera
extensive disease in a Hispanic Endocrinol
Baroli A, Pedrazzini Anaplastic thyroid carcinoma.
Minerva
L, Lomuscio G,
Practical aspects of multimodal
Endocrinol
Marzolitherapy and data emerging fromSo YK, Son YI, Hong Subclinical lymph nodeSD, Seo MY, Baek
metastasis in papillary thyroid Surgery
CH, Jeong HS, Chung microcarcinoma: a study of 551
Should we routinely offer a
Clin Oncol
Gerrard GE, O'Toole
second admission for(R CollL, Roberts
radioiodine to patients with
Radiol)To the editor: Long-term
World J
Bertagna F, Giubbini
follow-up of patients with
Surg
Malterling RR,
Differentiated thyroid cancer inAndersson RE,
a Swedish county--long-term Acta Oncol
Falkmer S, Falkmer
results and quality of life.
U, Nilehn E, Jarhult

2010 11(10)962-72

2010 629-40

2010 34(6)1222-312010 61(5)454-72010 57(8)364-92010 38(9)506-82010 141(3)233-82010 46(4)268-742010 20(5)555-602010 23(1-2) 59-64
2010 35(1)9-162010 148(3)526-31

2010 22(2)136-92010 34(8)1988-9; author reply 12010 49(4)454-9Verburg FA, Stokkel
No survival difference after
MP, Duren C,
successful (131)I ablation
Eur J Nucl
Verkooijen RB, Mader
between patients with initially Med Mol
2010
U, van Isselt JW,
low-risk and high-risk
Imaging
Marlowe RJ, Smitdifferentiated thyroid cancer.
JW, Reiners C,
Grant CS, Stulak JM, Risks and adequacy of anThompson GB,
optimized surgical approach to World J
2010
Surg
Richards ML, Reading the primary surgicalCC, Hay
management of papillary thyroid
Yipintsoi T,
Mortality-related factors inWorld J
Premprabha T,
1056 radioiodine-treated2010
Geater A,
patients with well-differentiated Surg
Thientunyakij T,
thyroid cancer in southern
Asli IN, Baharfard N, Relation between clinical andShafiei B, Tabei F,
laboratory parameters with
Radiat Prot
2010
Javadi H, Seyedabadi radiation dose rates from
Dosimetry
M, Nabipour I, Assadi patients receiving iodine-131
Wang J, Yuan H, Ma Interstitial 125I seeds
Q, Liu X, Wang H,
Med Oncol 2010
implantation to treat spinal
Jiang Y, Tian S, Yang metastatic and primary
A risk-adapted approach to theCancerTuttle RM, Rondeau
use of radioactive iodine and2011
Control
G, Leeexternal beam radiation in the
Verburg FA, Luster (131)I therapy in patients with
Nuklearmedi
benign thyroid disease does not
M, Lassmann M,
2011zin
Reinersconclusively lead to a higher
Hurtado-Lopez LM, Low-risk papillary thyroid
Melchor-Ruan J,
cancer recurrence in patientsBasurto-Kuba E,
treated with total
Cir Cir
2011
Montes de Ocathyroidectomy and adjuvant
Duran ER, Pulidotherapy vs. patients treatedwith partial thyroidectomy.
Cejudo A, AthieFallahi B, Adabi K,
Incidence of second primary
Majidi M, Fardmalignancies during a long-term
Clin Nucl
Esfahani A, Heshmat surveillance of patients with2011
Med
R, Larijani B,
differentiated thyroid carcinoma
in relation to radioiodine
Haghpanah
Radioactive iodine 1311 (RAI) Pediatr
treatment. The nearest to the Endocrinol 2011
Lubin
"magic bullet" but should
Rev
Papendieck P,
Differentiated thyroid
Gruneiro-Papendieck
J Pediatr
carcinoma: presentation and
L, Venara M, Acha O,
Endocrinol 2011
follow-up in children and
Maglio S, Bergada I,
Metabadolescents.
ChiesaOzkan E, Soydal C, Differentiated thyroid
J Pediatr
2011
Araz M, Kucuk
carcinomas in childhood:
Endocrinol
Nixon IJ, Ganly I,
The impact of microscopic
Patel S, Palmer FL, extrathyroid extension on
Surgery
2011
Whitcher MM, Tuttle outcome in patients with
RM, Shaha AR, Shah clinical T1 and T2 wellIn differentiated thyroid cancer,
Vaisman F, Tala H,
an incomplete structuralThyroid
2011
Grewal R, Tuttle
response to therapy is
associated with significantly

37(2)276-8334(6)1239-46

34(2)

230-6

138(4)

376-8127(2)319-26

18(2)

89-95

50(3)

93-9; quiz N2079(2)118-2536(4)277-82

9(1)

415-6

24(9-10) 743-8

24(9-10) 739-42
150(6)

1242-921(12)

1317-22

Papillary thyroid carcinoma
Soyluk O, Boztepe H, patients assessed to be at low
Thyroid
Aral F, Alagol F,
or intermediary risk afterOzbey
primary treatment are at
greater risk of long term
Kim EY, Kim TY, Kim Effects of different doses of
WG, Yim JH, Han JM, radioactive iodine for remnant
Nucl MedRyu JS, Hong SJ,
ablation on successful ablation
CommunYoon JH, Gong G,
and on long-term recurrences
Kim WB, Shongin patients with differentiatedCastagna MG, Maino Delayed risk stratification, to
F, Cipri C, Belardini include the response to initial Eur J
Endocrinol
V, Theodoropoulou A, treatment (surgery andCevenini G, Paciniradioiodine ablation), has better
Huang BY, Lin JD,
Therapeutic outcomes of
Chao TC, Lin KJ,
papillary thyroid cancer
Oncology
Hseuh C, Tsang
patients in different risk groups.
Iyer NG, Morris LG, Rising incidence of second
Tuttle RM, Shaha AR, cancers in patients with lowCancer
Ganlyrisk (T1N0) thyroid cancer who
van Dijk D, Plukker
JT, van der HorstThe value of detectable
Clin
Schrivers AN, Jansen thyroglobulin in patients with
Endocrinol
L, Brouwers AH,
differentiated thyroid cancer(Oxf)
Muller-Kobold A,
after initial (1)(3)(1)I therapy.
Sluiter WJ, Links
Hieu TT, Russell AW, Cancer risk after medical
EndocrCuneo R, Clark J,
exposure to radioactive iodine Relat
Kron T, Hall P, Doi
in benign thyroid diseases: a
CancerRadioiodine remnant ablation: Endocr
Haugencurrent indications and dosing Pract
Zhao Y, Zhang Y, Liu Prognostic factors for
Tumori
XJ, Shidifferentiated thyroid carcinoma
A randomized equivalence trial
Bal C, Chandra P,
Nucl Medto determine the optimum dose
Kumar A, Dwivedi
Communof iodine-131 for remnant
Daumerie C, Boschi Is Recombinant Human TSH a Eur Thyroid
A, Perros
Trigger for Graves'
J
Iodine or Not (IoN) for low-risk Clin Oncol
Mallick U, Harmer C,
differentiated thyroid cancer:(R CollHackshaw A, Mossthe next UK National Cancer
Radiol)Adedapo KS, FadijiHigh default rate in thyroid
Afr J MedIO, Orunmuyi AT,
cancer management in Ibadan,
Med Sci
Ejeh JE, Osifo
Nigeria: a need for healthBrownlie BJ, Turner Deaths due to differentiatedN Z Med J
J, Abdelaal
thyroid cancer: a South Island,
Ibrahimpasic T, Nixon Undetectable thyroglobulin
IJ, Palmer FL,
after total thyroidectomy inSurgery
Whitcher MM, Tuttle patients with low- and
RM, Shaha A, Patel intermediate-risk papillary
SG, Shah JP, Ganly thyroid cancer--is there a need
Recombinant human thyroid
Hugo J, Robenshtok
stimulating hormone-assisted
E, Grewal R, Larson
Thyroid
radioactive iodine remnant
S, Tuttle
ablation in thyroid cancer
Prognostic implication of
Lim I, Kim SK, Hwang
thyroglobulin and quantified
Ann Nucl
SS, Kim SW, Chungwhole body scan after initialMed
KW, Kang HS, Leeradioiodine therapy on early2011 21(12)1301-82011 32(10)954-92011 165(3)441-62011 80(1-2) 123-9
2011 117(19) 4439-46

2011 74(1)104-102012 19(5)645-552012 18(4)604-102012 98(2)233-72012 33(10)1039-47

2012 1(2)105-92012 24(3)159-61

2012 41 Suppl 105-9
2012 125(136313-21

2012 152(6)1096-105

2012 22(10)1007-152012 26(10)777-86

Rosenbaum-Krumme (1)(8)F-FDG PET/CT changes Eur J Nucl
SJ, Gorges R,
therapy management in highMed Mol
2012
Bockisch A, Binse
risk DTC after first radioiodine Imaging
Kutluhan A, Yalciner Papillary thyroid carcinoma with
Kulak Burun
G, Bozdemir K,
metastasis to the
Bogaz Ihtis 2012
Ozdemir E, Tarlak B, temporooccipital skull: a case
Derg
Bilgenreport.
Ozpacaci T,
Intraocular and orbitalAnn
Mulazimoglu M,
metastasis as a rare form ofEndocrinol 2012
Tamam MO, Leblebici clinical presentation of insular(Paris)C, Yildiz K, Uyanik E, thyroid cancer.
Hartl DM, Leboulleux
Optimization of staging of theS, Al Ghuzlan A,
neck with prophylactic central
Baudin E, Chami L,
Ann Surg
2012
and lateral neck dissection for
Schlumberger M,
papillary thyroid carcinoma.
Travagli
Kim K, Kim SJ, Kim Clinical significance of diffuse
IJ, Kim YK, Kim BS, hepatic visualization and thyroid Onkologie
2012
Pak
bed uptake on post-ablative
Enomoto Y, Enomoto Clinical features, treatment, andK, Uchino S, Shibuya long-term outcome of papillary World J
2012
H, Watanabe S,
thyroid cancer in children and Surg
Noguchiadolescents without radiation
Barbesino G,
Thyroid lobe ablation with
Goldfarb M, Parangi radioactive iodine as an
Thyroid
2012
S, Yang J, Ross DS, alternative to completion
thyroidectomy after
Daniels
Schvartz C,
Bonnetain F,
Dabakuyo S, Gauthier Impact on overall survival of
J ClinM, Cueff A, Fieffe S, radioactive iodine in low-risk
Endocrinol 2012
Pochart JM, Cochet differentiated thyroid cancer
MetabI, Crevisy E, Dalac A, patients.
Papathanassiou D,
ToubeauLang BH, Wong IO,
Risk of second primary
Surgery
2012
Wong KP, Cowlingmalignancy in differentiated
BJ, Wanthyroid carcinoma treated with
Qin C, Cau W, Zhang Correlation ofClin Nucl
Y, Mghanga FP, Lan clinicopathological features and
2012
Med
X, Gao Z, An
expression of molecularRadioiodine remnant ablation in
Nuklearmedi
Vrachimis A, Schober
differentiated thyroid cancer
2012
zin
O, Riemann
after combined endogenous andHuang CH, Chao TC, Therapeutic outcome andPediatr Surg
Hseuh C, Lin KJ, Ho prognosis in young patients with2012
Int
TY, Lin SF, Lin
papillary and follicular thyroid
de Meer SG, Dauwan Not the number but theM, de Keizer B, Valk location of lymph nodes
World J
2012
GD, Borel Rinkes IH, matters for recurrence rate and Surg
Vriensdisease-free survival in patients
Ito Y, Kudo T,
Prognostic factors forWorld J
Kobayashi K, Miya A, recurrence of papillary thyroid
2012
Surg
Ichihara K, Miyauchi carcinoma in the lymph nodes,
Determining the extent of
Wu G, Fraser S, Pai
lateral neck dissection
Head Neck 2012
SI, Farrag TY,
necessary to establish regional
Ladenson PW, Tufano
disease control and avoid39(9)1373-80

22(3)

160-3

73(3)

222-4

255(4)

777-83

35(3)

82-6

36(6)

1241-622(4)369-7697(5)1526-35

151(6)

844-50

37(3)

e40-6

51(3)

67-72

28(5)

489-9436(6)1262-736(6)1274-834(10)

1418-21

Vianello F,
Clinical outcome of low-risk
Mazzarotto R, Mian differentiated thyroid cancer
Clin Oncol
C, Lora O, Saladini G, patients after radioiodine(R Coll2012
Servodio O, Basso M, remnant ablation andRadiol)Pennelli G, Pelizzo
recombinant human thyroidSun XS, Guevara N,
Fakhry N, Sun SR,[Radiation therapy in thyroid
Cancer
2013
Marcy PY, Santini J, cancer].
Radiother
Bosset JF, Thariat
A systematic review and metaLang BH, Ng SH, Lau
analysis of prophylactic central
Thyroid
2013
LL, Cowling BJ, Wongneck dissection on short-term
KP, Wanlocoregional recurrence in
Azizmohammadi Z,
A study of the time of hospital
Tabei F, Shafiei B,
discharge of differentiatedBabaei AA, JukandanHell J Nucl
thyroid cancer patients after
2013
SM, Naghshine R,Med
receiving iodine-131 for thyroid
Javadi H, Nabipour I,
remnant ablation treatment.
Assadi M, AsliAn YS, Yoon JK, Lee Symptomatic late-onset
Ann Nucl
SJ, Song HS, Yoon
sialadenitis after radioiodine
2013
Med
SH, Jotherapy in thyroid cancer.
Kim HJ, Kim NK, Choi Radioactive iodine ablation
Clin
JH, Kim SW, Jin SM, does not prevent recurrences
Endocrinol 2013
Suh S, Bae JC, Min in patients with papillary thyroid(Oxf)
microcarcinoma.
YK, Chung JH, Kim
Kruijff S, Aniss AM,
Decreasing the dose ofChen P, Sidhu SB,
radioiodine for remnant ablation
Delbridge LW,
does not increase structural
Surgery
2013
Robinson B, Cliftonrecurrence rates in papillary
Bligh RJ, Roach P,
thyroid carcinoma.
Gill AJ, Learoyd D,[Management and prognostic
Zhonghua
Liu WS, Zhang GF, Xu
2013
factors for 119 patients with
Zhong Liu
Wienhold R, Scholz The management of thyroid
Dtsch
M, Adler JR, G Nster nodules: a retrospective
2013
Arztebl Int
C, Paschke
analysis of health insurance
Young S, Harari A,
Effect of reoperation on
Smooke-Praw S,
outcomes in papillary thyroid
Surgery
2013
Ituarte PH, Yehcancer.
Pedrazzini L, Baroli Cancer recurrence in papillary
Minerva
A, Marzoli L,
thyroid microcarcinoma: a
2013
Endocrinol
Guglielmi R, Papini
multivariate analysis on 231
Vrachimis A,
Peace of mind for patients with Nuklearmedi
Riemann B, Gerss J,
2013
differentiated thyroid cancer? zin
Maier T, Schober
Radioiodine remnant ablation in J Med
2013
Saengsuda
low-risk differentiated thyroid Assoc Thai
Park S, Jeong JS,
Differentiated thyroid
Ryu HR, Lee CR,
carcinoma of children and
J KoreanPark JH, Kang SW,
adolescents: 27-year
2013
Med SciJeong JJ, Nam KH, experience in the yonsei
Chung WY, Park
university health system.

24(3)

162-8

17(3)

233-43; quiz 255-6, 2523(9)1087-98

16(2)

103-6

27(4)

386-9178(4)614-20154(6)

1337-44; discussion 13

35(10)

778-82110(49) 827-34
154(6)

1354-61; discussion 1338(3)269-7952(4)115-2096(5)614-24

28(5)

693-9

Reiners C, Biko J,
Twenty-five years after
Haenscheid H,
Chernobyl: outcome of
J ClinHebestreit H, Kirinjuk radioiodine treatment in
S, Baranowski O,
children and adolescents with Endocrinol 2013
Marlowe RJ,
very high-risk radiation-induced Metab
Demidchik E, Drozd differentiated thyroid
V, Demidchik
carcinoma.
Aggressive variants of papillary
Kuo EJ, Goffredo P,
thyroid microcarcinoma are
Thyroid2013
Sosa JA, Roman
associated with extrathyroidal
Castagna MG,
Post-surgical thyroid ablation
Cevenini G,with low or high radioiodine
Eur J
Theodoropoulou A,
activities results in similar
2013
Maino F, Memmo S, outcomes in intermediate risk Endocrinol
Claudia C, Belardini differentiated thyroid cancer
V, Brianzoni E, Pacini patients.
Meixner M, Hellmich Disease-free survival in
M, Dietlein M, Kobe papillary and follicular thyroid
Nuklearmedi
2013
C, Schicha H,
carcinoma. Comparison
zin
Schmidt
between UICC 5th and 7th
Lango M, Flieder D, Extranodal extension of
Arrangoiz R, Veloski metastatic papillary thyroid
Thyroid
2013
C, Yu JQ, Li T,
carcinoma: correlation with
Burtness B, Mehra R, biochemical endpoints, nodal
persistence, and systemic
Galloway T, Ridge
Hod R, Bachar G,
Insular thyroid carcinoma: a
Am J
2013
Sternov Y, Shvero
retrospective clinicopathologic Otolaryngol
Ito Y, Hirokawa M,
Prognostic factors of minimally
Masuoka H, Yabuta
invasive follicular thyroidT, Kihara M,
carcinoma: extensive vascular Endocr J
2013
Higashiyama T,
invasion significantly affects
Takamura Y,
patient prognosis.
Kobayashi K, Miya A,
Ibrahimpasic T,
Ghossein R, Carlson Poorly differentiated thyroid
DL, Chernichenko N, carcinoma presenting with
Nixon I, Palmer FL,
gross extrathyroidal extension:
Thyroid
2013
Lee NY, Shaha AR, 1986-2009 Memorial SloanPatel SG, Tuttle RM, Kettering Cancer Center
Balm AJ, Shah JP,
experience.
Ganly
Absence of bone marrow
toxicity in elderly patients
Am J Clin
Amdur RJ, Dan T,
2013
treated with recombinantOncol
Mazzaferri
human thyroid-stimulating
Treatment decisions andIsr MedHilly O, Stern-Shavit
adherence to guidelines in the2014
Assoc J
S, Iran S, Feinmesser
treatment of low risk papillary
Rokni H, Sadeghi R, Efficacy of different protocols Int J
Moossavi Z, Treglia of radioiodine therapy for
Endocrinol 2014
G, Zakavi
treatment of toxic nodular
MetabWang TS, Goffredo P, Papillary thyroid
World J
2014
Sosa JA, Roman
microcarcinoma: an overSurg
Iacobone M, Jansson Multifocal papillary thyroid
Langenbeck
S, Barczynski M,
carcinoma--a consensus report2014s Arch Surg
Goretzkiof the European Society of
Karyampudi A,
Radioiodine therapy in patients Indian J
Hamide A, Halanaik with Graves' disease and the
Endocrinol 2014
D, Sahoo JP,
effects of prior carbimazole
Metab

98(7)

3039-48

23(10)

1305-11

169(1)

23-9

52(3)

71-80

23(9)

1099-105

34(4)

292-5

60(5)

637-4223(8)997-1002

36(4)348-5316(9)548-5212(2)e1442438(9)2297-303

399(2)

141-5418(5)688-93

Long-term survival in
J ClinVerburg FA, Mader U,
differentiated thyroid cancer is Endocrinol 2014
Reiners C, Hanscheidworse after low-activity initial Metab
Guy A, Hirsch D,
Papillary thyroid cancer: factors
Shohat T, Bachar G,
J Clininvolved in restaging N1 disease
Tirosh A, Robenshtok
Endocrinol 2014
after total thyroidectomy andE, Shimon I,
Metabradioactive iodine treatment.
Benbassat
Liu B, Peng W, Huang Thyroid cancer: radiation safety
R, Tian R, Zeng Y,
precautions in 131I therapy
Radiology
2014
Kuang
based on actual biokinetic
Ito Y, Miyauchi A, Ito
Prognosis and prognostic
M, Yabuta T,
factors of differentiated thyroid
Masuoka H,
carcinoma after the appearance Endocr J
2014
Higashiyama T,of metastasis refractory to
Fukushima M,
radioactive iodine therapy.
Kobayashi K, Kihara
Lupoli R, Cacciapuoti
M, Tortora A, Barba
L, Verde N, Romano Clinical outcome indifferentiated thyroid carcinoma Int J Surg 2014
F, Vastarella M,
Fonderico F, Masone and microcarcinoma.
S, Milone M, Lupoli G,
Lupoli
Tresoldi AS, Sburlati
LF, Rodari M,
Radioiodine ablation with 1,850
Schinkelshoek M,
Perrino M, De Leo S, MBq in association with rhTSH J Endocrinol
2014
in patients with differentiated Invest
Montefusco L,
Colombo P, Arosio M, thyroid cancer.
Lania AG, Fugazzola
L, Chiti
Astl J, Chovanec M, Thyroid carcinoma surgery in
Int J
Lukes P, Katra R,
children and adolescents - 15 Pediatr
2014
Dvorakova M, Vlcek years experience surgery of
Otorhinolary
ngol
P, Sykorova P, Betka pediatric thyroid carcinoma.
Hasbek Z, Turgut B, Importance of postoperative
Asian Pac J
Kilicli F, Altuntas EE, stimulated thyroglobulin level at
2014
Cancer Prev
Yucel
the time of 131I ablation
Ardito G, Avenia N, Papillary thyroid
Giustozzi E, Salvatori microcarcinoma: proposal of
Ann Ital Chir 2014
M, Fadda G, Ardito F, treatment based on histological
Revelliprognostic factors evaluation.
De Crea C, Raffaelli Actual incidence and clinical
M, Sessa L, Ronti S, behaviour of follicular thyroid
ScientificWo
2014
Fadda G, Bellantone carcinoma: an institutional
rldJournal
C, Lombardi
experience.
Central lymph node metastasis
J Korean
Lee J, Song Y, Soh is an important prognostic
2014
Med Sci
factor in patients with papillary
Han JM, Kim WG, Kim Effects of low-dose and highTY, Jeon MJ, Ryu
dose postoperative radioiodine
Thyroid2014
JS, Song DE, Hongtherapy on the clinical outcome
SJ, Shong YK, Kim
in patients with small
Comparison of radioiodine
EndocrGoldfarb M, Sener
2014
utilization in adolescent andPract
Thyroid ablation with 1.1 GBq
2014
Rosario PW, Calsolari (30 mCi) iodine-131 in patients Thyroidwith papillary thyroid carcinoma

99(12)

4487-96

99(11)

4167-73273(1)

211-9

61(8)

821-4

12 Suppl S148-51

37(8)709-14

78(7)

990-4

15(6)

2523-7

85(1)

1-5

2014

952095

29(1)

48-52

24(5)

820-5

20(5)

405-1124(5)826-31

Kotb MH, Zaher AM, Prognostic value of p27 inAppl
Abd El-Wahab MA,
follicular thyroid carcinoma and Immunohist
2014
Abulkheir IL, Hussein its relation to radioactive iodine ochem Mol
Morphol
M, Salem
response: does it aid in the
Kim SK, Yun GY, Kim Severe hyponatremia following
KH, Park SK, Choi
radioactive iodine therapy inThyroid
2014
HY, Ha SK, Park
patients with differentiatedJeon MJ, Kim WG,
Modified dynamic risk
Park WR, Han JM,
stratification for predicting
Eur J
Kim TY, Song DE,recurrence using the response
2014
Endocrinol
Chung KW, Ryu JS, to initial therapy in patients
Hong SJ, Shong YK, with differentiated thyroid
Zoghlami A, Roussel BRAF mutation in papillary
Eur Ann
F, Sabourin JC, Kuhn thyroid carcinoma: predictive
Otorhinolary
2014
JM, Marie JP,
value for long-term prognosis ngol Head
Neck Dis
Dehesdin D, Choussy and radioiodine sensitivity.
Prognostic factors affecting
Akkas BE, Demirel
disease-specific survival in
Thyroid
2014
BB, Vuralpatients with recurrent and/or
metastatic differentiatedBiondi B, Bartalena L, The 2015 European Thyroid
Eur Thyroid
Cooper DS, Hegedus Association Guidelines on
2015
JL, Laurberg P, Kahaly Diagnosis and Treatment of
A Systematic Review of
Oncol Res
2015
Xu G, Wu T, Ge L, Li
Adjuvant Interventions for
Treat
Ruel E, Thomas S,
Adjuvant radioactive iodine
J ClinDinan M, Perkins JM, therapy is associated with
Endocrinol 2015
Roman SA, Sosa
improved survival for patients Metab
Use of evidence-based
Sacks W, Wong RM,
guidelines reduces radioactive Thyroid
2015
Bresee C, Braunstein
iodine treatment in patients
Recombinant human thyrotropin Q J Nucl
Fu H, Ma C, Tang L,
2015
versus thyroid hormone
Med MolWu F, Liu B, Wang
withdrawal in radioiodine
Imaging
Worden F, Fassnacht
M, Shi Y, Hadjieva T,
Bonichon F, Gao M,
Fugazzola L, Ando Y, Safety and tolerability of
Endocrsorafenib in patients with
Hasegawa Y, Park
Relat
2015
DJ, Shong YK, Smit radioiodine-refractory thyroid
Cancercancer.
JW, Chung J,
Kappeler C,
Meinhardt G,
Schlumberger M,
Sawka AM, Straus S, Decision aid on radioactive
Rodin G, Thorpe KE, iodine treatment for early stage
Trials
2015
Ezzat S, Gafni A,
papillary thyroid cancer: update
Goldstein
to study protocol with followJacob JJ, Stephen C, No impact of dietary iodine
Indian J
Paul TV, Thomas N, restriction in short term
Endocrinol 2015
Oommen R, Seshadri development of hypothyroidism Metab
Czepczynski R,
Arch
Matysiak-Grzes M,
Peptide receptor radionuclide
Immunol
Gryczynska M,
therapy of differentiated thyroid
2015
Ther Exp
Baczyk M,
cancer: efficacy and toxicity.
(Warsz)Wyszomirska A,
Shen J, Wang S,
Skull metastasis from follicular
Int J Clin
Zhao X, Shao X,
thyroid carcinoma: report of2015
Exp Pathol
Jiang X, Dai Y, Xu S, three cases and review of

22(7)

511-7

24(4)

773-7

170(1)

23-30

131(1)

7-13

24(2)

287-954(3)149-6338(7-8) 368-72
100(4)

1529-3625(4)377-85

59(1)

121-8

22(6)

877-87

16

302

19(1)

60-5

63(2)

147-548(11)15285-93

Using ultrasound radio
frequency technology to assess Arch Med
Kang
2015
regression of the structure and Sci
function of the carotid artery
Kao YH, Gan HK,
Gender, Race, and Age at
Zaheer S, Lam WW, Diagnosis as Risk Factors for Oncol Res
2015
Loke KS, Wong WY, Metastasis or Recurrence
Treat
Ng DC, Gohamong 1,657 Thyroid Cancer
Al-Qahtani KH, Al
Adjuvant Radioactive iodine 131 J
Asiri M, Tunio MA,
ablation in papillary
Otolaryngol
2015
Aljohani NJ, Bayoumi microcarcinoma of thyroid:
Head Neck
Y, Fatani H, AlHadab Saudi Arabian experience
Surg
Zaman MU, Fatima N, Predictive value of pyramidal
Indian J
Zaman U, Sajjad Z,
lobe, percentage thyroid uptake
2015
Nucl Med
Zaman A, Tahseen
and age for ablation outcome
SERIAL NECK ULTRASOUND
Yang SP, Bach AM, IS MORE LIKELY TO IDENTIFY Endocr
2015
FALSE-POSITIVE
Pract
Tuttle RM, FishABNORMALITIES THAN
Ryodi E, Metso S,
Cancer Incidence and Mortality
J ClinJaatinen P, Huhtala in Patients Treated Either With
Endocrinol 2015
H, Saaristo R,
RAI or Thyroidectomy for
MetabValimaki M, Auvinen Hyperthyroidism.
Liu FH, Kuo SF,
Postoperative recurrence of
J SurgHsueh C, Chao TC, papillary thyroid carcinoma with
2015
Oncol
lymph node metastasis.
Lin
Ahn HY, Min HS, Yeo
Y, Ma SH, Hwang Y,Radioactive Iodine Therapy Did
An JH, Choi HS,
J ClinNot Significantly Increase theKeam B, Im SA, Park
Endocrinol 2015
Incidence and Recurrence ofDJ, Park IA, Noh DY,
MetabSubsequent Breast Cancer.
Youn YK, Chung JK,
Cho BY, Park SK,
Increased Risk of Leukemia
Seo GH, Cho YY,
After Radioactive Iodine
Thyroid
2015
Chung JH, Kim
Therapy in Patients with
Increased risk of second
Marti JL, Jain KS,
primary malignancy in pediatric Thyroid
2015
Morrisand young adult patients
Orlov S, Salari F,
Post-operative stimulated
Kashat L, Freeman
thyroglobulin and neck
Endocrine 2015
JL, Vescan A,
ultrasound as personalized
Witterick IJ, Walfish criteria for risk stratification
Gamper EM, Wintner
LM, Rodrigues M,
Persistent quality of life
Eur J Nucl
Buxbaum S, Nilica B, impairments in differentiated
Med Mol
2015
Singer S, Giesinger thyroid cancer patients: results
Imaging
JM, Holzner B,
from a monitoring programme.
Virgolini
Semrad TJ, Semrad Initial treatment patterns in
AM, Farwell DG,
younger adult patients with
Thyroid2015
Chen Y, Cressdifferentiated thyroid cancer inPreablation 131-I scans withJ ClinAvram AM, Esfandiari
SPECT/CT contribute to
Endocrinol 2015
NH, Wong
thyroid cancer risk stratification Metab
Lorenz R, Buck A,[In-patient nuclear medicine
Nuklearmedi
2015
Reiners
therapy in Germany from 2010 zin

11(6)1236-43

38(12)

679-82

44

51

30(4)

309-1321(12)

1372-9100(10) 3710-7

112(2)

149-54100(9)

3486-9325(8)927-34

25(6)

681-7

50(1)

130-7

42(8)

1179-8825(5)509-13100(5)

1895-902

54(2)

61-8

Kiernan CM, Parikh
AA, Parks LL,
Solorzano
Wang LY, Palmer FL,
Nixon IJ, Tuttle RM,
Shah JP, Patel SG,
Shaha AR, Ganly
Maier TM, Schober
O, Gerss J, Gorlich
D, Wenning C,
Schaefers M,
Riemann B,
Shivaprasad C,
Prasanna Kumar

Use of radioiodine after thyroid
lobectomy in patients withdifferentiated thyroid cancer:
Lateral Neck Lymph NodeCharacteristics Prognostic of
Outcome in Patients with
Clinically Evident N1b Papillary

J Am Coll
Surg

2015 220(4)617-25

Ann Surg
Oncol

2015 22(11)3530-6

Differentiated thyroid cancer
patients more than 60 years old
J Nucl Med 2015 56(2)paradoxically show anincreased life expectancy.

190-5

Long-term carbimazole
Indian J
2015
pretreatment reduces the
Endocrinol
Clinical management andoutcomes in patients with
Qiu ZL, Shen CT, Luo
Thyroid2015
hyperfunctioning distantmetastases from differentiatedGarg A, Chopra S,
Differentiated thyroid cancer in
J Geriatr
Ballal S,
patients over 60 years of age at
2015
Oncol
Soundararajan R, Bal presentation: a retrospective
Khang AR, Cho SW,
The risk of second primary
Choi HS, Ahn HY,malignancy is increased inClin
Yoo WS, Kim KW,
differentiated thyroid cancer
Endocrinol 2015
Kang KW, Yi KH, Park
patients with a cumulative(Oxf)
DJ, Lee DS, Chung(131)I dose over 37 GBq.
JK, Cho BY, Park
Prognostic significance of
Kim KJ, Kim SM, Leetumor multifocality in papillary Ann Surg2015
YS, Chung WY, Chang
Oncol
thyroid carcinoma and its
HS, Park
relationship with primary tumor
The impact of locoregional
Clin
Su DH, Chang SH,
recurrences and distantEndocrinol 2015
Chang
metastases on the survival of (Oxf)
Scott E, Learoyd D, Therapeutic options in papillary Future
2016
Clifton-Blighthyroid carcinoma: current
Oncol[Ablative Radioiodtherapie bei
Nuklearmedi
Dietlein M, Drzezga niedrigem und intermediarem
2016
zin
Rezidivrisiko. Hohere
Radioiodine therapy versus
antithyroid drugs in Graves'
Br J Radiol 2016
Wang J, Qindisease: a meta-analysis of
RISK FACTORS FOR
Chen P, Feng HJ,
NONREMISSION AND
EndocrOuyang W, Wu JQ,
PROGRESSION-FREE
2016
Pract
Wang J, Sun YG, Xian SURVIVAL AFTER I-131
JL, Huang
THERAPY IN PATIENTS WITH
LUNG METASTASIS FROM
Risk of second primary breast
Nucl Med
Zhang Y, Liang J, Li
cancer after radioactive iodine
2016
CommunH, Cong H, Lin
treatment in thyroid cancer: a
Li JH, He ZH, Bansal Low iodine diet in differentiated Clin
2016
V, Hennessey
thyroid cancer: a review.
Endocrinol[Lenvatinib in radioiodine
de la Fouchardiere
Bull Cancer 2016refractory thyroid carcinomas].

19(1)

84-8

25(2)

229-37

6(1)

29-37

83(1)

117-2322(1)125-3182(2)286-9412(22)

2603-2613

55(3)

71-6
2016041822(9)1048-56

37(2)

110-5

84(1)

3-12

103(11) 905-910

Klein Hesselink EN, Effects of Radioiodine
Brouwers AH, deTreatment on Salivary GlandJong JR, van derFunction in Patients with
J Nucl Med
Horst-Schrivers AN, Differentiated Thyroid
Coppes RP, Lefrandt Carcinoma: A Prospective
JD, Jager PL, Vissink Study.
Gao X, Zhang X,
Is papillary thyroid
Medicine
Zhang Y, Hua W,
microcarcinoma an indolent(Baltimore)
Maimaiti Y, Gaotumor?: A retrospective study
Brose MS, Cabanillas Vemurafenib in patients with
ME, Cohen EE, Wirth BRAF(V600E)-positive
Lancet
LJ, Riehl T, Yue H,
metastatic or unresectable
Oncol
Sherman SI, Sherman papillary thyroid cancer
Tun NN, Beckett G, Thyrotropin Receptor Antibody
Zammitt NN,
Levels at Diagnosis and After Thyroid
Strachan MW, Seckl Thionamide Course Predictla Cour JL, Andersen Radioiodine Therapy Does Not
UB, Sorensen CH,
Change the Atherosclerotic
ThyroidNygaard B, Jensen
Burden of the Carotid Arteries.
Canto AU,
Comparison of Fixed versus
Endocrinol
Dominguez PN,
Calculated Activity of
MetabJimeno CA, Obaldo Radioiodine for the Treatment (Seoul)
Louvet C, De Bellis
A, Pereira B,
Time course of Graves'
Bournaud C, Kelly A,
orbitopathy after total
Medicine
Maqdasy S, Roche B,
thyroidectomy and radioiodine (Baltimore)
Desbiez F, Borsontherapy for thyroid cancer.
Chazot F, Tauveron I,
Batisse-Lignier
Hollingsworth B,
Senter L, Zhang X,
Brock GN, Jarjour W,
Risk Factors of 131I-Induced
J ClinNagy R, Brock P,
Salivary Gland Damage in
Endocrinol
Coombes KR, Kloos
Thyroid Cancer Patients.
Metab
RT, Ringel MD, Sipos
J, Lattimer I, Carrau
R, Jhiang
Deutschmann MW,
Practice patterns amongJ
Chin-Lenn L,
thyroid cancer surgeons:
Otolaryngol
Nakoneshny SC, Dort implications of performing a
Head Neck
JC, Pasieka JL,
prophylactic central neck
Surg
Chandarana
dissection.
A review of treatment options J
for Graves' disease: why total Community
Mohan V, Lind
thyroidectomy is a viable option Hosp Intern
Elevated serum thyroglobulin
Matthews TJ, Chualevels at the time of ablative
J Laryngol
E, Gargya A, Clark J,
radioactive iodine therapy
Otol
Gao K, Elliott
indicate a worse prognosis in
Use of imaging tests after
Banerjee M, Wiebel
primary treatment of thyroid
BMJ
JL, Guo C, Gay B,
cancer in the United States:
Haymartpopulation based retrospective

2016 57(11)1685-1691

2016 95(40)e50672016 17(9)1272-822016 26(8)1004-92016 26(7)965-712016 31(1)168-732016 95(48)e54742016 101(11) 4085-4093

2016 45(1)552016 6(4)32369

2016 130 SuppS50-3

2016 354

i3839

Cramon P, Winther
Quality-of-Life Impairments
KH, Watt T, Bonnema
Persist Six Months After
SJ, Bjorner JB,
Treatment of Graves'Ekholm O, Groenvold
Thyroid2016
Hyperthyroidism and Toxic
M, Hegedus L, FeldtNodular Goiter: A Prospective
Rasmussen U,
Cohort Study.
Rasmussen
Efficacy of adjuvant therapy
Rosario PW, Mourao with 3.7 GBq radioactive iodine Nucl Med
2016
in intermediate-risk patients
Commun
GF, Calsolariwith 'higher risk features' andWinter J, Winter M, Patients with high-risk
Krohn T, Heinzel A, differentiated thyroid cancer
Clin
Behrendt FF, Tuttle have a lower I-131 ablation
Endocrinol 2016
RM, Mottaghy FM,(Oxf)
success rate than low-risk
Verburg
ones in spite of a high ablation
Klein Hesselink MS,
Nies M, Bocca G,
Brouwers AH,
Burgerhof JG, van
Dam EW, Havekes B,
van den HeuvelEibrink MM, Corssmit Pediatric Differentiated Thyroid J Clin
Carcinoma in The Netherlands: Endocrinol 2016
EP, Kremer LC,
Netea-Maier RT, van A Nationwide Follow-Up Study. Metabder Pal HJ, Peeters
RP, Schmid KW, Smit
JW, Williams GR,
Plukker JT, Ronckers
CM, van Santen HM,
Tissing WJ, Links
Lin CM, Yeh PT,
Association Between 131I
Doyle P, Tsan YT,Treatment for Thyroid Cancer J Nucl Med 2016
Chen
and Risk of Receiving Cataract
Ruhlmann M, Binse I, Initial [18F]FDG PET/CT in
Nuklearmedi
high-risk DTC patients. A
Bockisch A,
2016
zin
Rosenbaum-Krumme three-year follow-up.
Prognostic Implications ofHeaton CM, Chang
Lymph Node Yield in Central
Thyroid2016
JL, Orloffand Lateral Neck Dissections
Low postoperative
Clin
Rosario PW, Mourao nonstimulated thyroglobulin as
Endocrinol 2016
GF, Calsolari
a criterion for the indication of(Oxf)
low radioiodine activity in
Prpic M, Kruljac I,
Re-ablation I-131 activity does
Kust D, Kirigin LS,
not predict treatment success
Endocrine 2016
Jukic T, Dabelic N,
in low- and intermediate-risk
Bolanca A, Kusic
patients with differentiatedRisk of Breast Cancer in
Lin CY, Lin CL,
Patients with Thyroid Cancer J Nucl Med 2016
Huang WS, Kao
Receiving or Not Receiving
Pathak KA, Klonisch Stage II differentiated thyroid J Surg
2016
TC, Nasoncancer: A mixed bag.
Oncol
So K, Smith RE,
Radiotherapy in wellANZ J Surg 2016
Davis
differentiated thyroid cancer: is
Lee DY, Won JK, Lee Changes of Clinicopathologic
SH, Park DJ, Jung
Characteristics and Survival
Thyroid
2016
KC, Sung MW, Wu
Outcomes of Anaplastic and
HG, Kim KH, Park YJ, Poorly Differentiated Thyroid26(8)1010-837(11)

1148-5385(6)926-931101(5)

2031-957(6)836-4155(3)99-10326(3)434-40

85(3)

453-8

52(3)

602-8

57(5)

685-90113(1)

94-7

86(9)

696-700

26(3)404-13

Teng CJ, Hu YW,
Use of Radioactive Iodine forChen SC, Yeh CM,
Thyroid Cancer and Risk of
J Natl2016
Chiang HL, Chen TJ, Second Primary Malignancy: A Cancer Inst
Liu
Nationwide Population-Based
Hakala TT, Sand JA, Increased risk of certain
Jukkola A, Huhtala
second primary malignancies in Int J Clin
2016
HS, Metso S,
patients treated for wellOncol
Kellokumpu-Lehtinen differentiated thyroid cancer.
Souza MC, Momesso Is radioactive iodine- 131
ArchDP, Vaisman F, Vieira treatment related to the
Endocrinol 2016
Neto L, Martins RA, occurrence of nonMetab
Corbo R, Vaisman
synchronous second primary
Scerrino G, Attard A,
Melfa GI, Raspanti C, Role of prophylactic central
DI Giovanni S, Attard neck dissection in cN0-papillary Minerva
2016
M, Inviati A, Mazzola thyroid carcinoma: results from Chir
S, Modica G, Gulotta a high-prevalence area.
G, Bonventre
Ballal S,
Intermediate-risk differentiated ClinSoundararajan R,
thyroid carcinoma patients who Endocrinol 2016
Garg A, Chopra S,
were surgically ablated do not (Oxf)
Jeon YW, Ahn YE,Radioactive iodine treatment
Asia Pac J
Chung WS, Choi HJ, for node negative papillary
2016
Clin OncolSuhthyroid cancer with capsular
Qin Y, Yao L, Shao F, Methodological Quality
Horm Metab2017
Yang K, Tian
Assessment of Meta-Analyses Res
Parker WA, Edafe O, Long-term treatment-related Pragmat
2017
Balasubramanianmorbidity in differentiatedObs ResComparison of curative effect Minerva
Yuan J, Lu X, Yue
2017of 131I and antithyroid drugs in Endocrinol
Kluijfhout WP,
Application of the new
Pasternak JD, Drake American Thyroid Association
2017
FT, Beninato T, Shen guidelines leads to a substantial Surgery
WT, Gosnell JE, Suh rate of completion total
thyroidectomy to enable
I, C L, DuhBrose MS, Worden
Effect of Age on the Efficacy
J Clin Oncol 2017
FP, Newbold KL, Guo and Safety of Lenvatinib in
M, Hurria
Radioiodine-RefractoryLow- and high-dose radioiodine
Ann Nucl
Qu Y, Huang R, Li
therapy for low-/intermediate2017
Medrisk differentiated thyroid
Giesecke P, Frykman All-cause and cardiovascular
V, Wallin G, Lonn S, mortality risk after surgery
Br J Surg
2017
Discacciati A, Torring versus radioiodine treatment
O, Rosenqvist
for hyperthyroidism.
Yang D, Xue J, Ma W, Prognostic factor analysis in
Nucl Med
Liu F, Fan Y, Rong J, 325 patients with Graves'
2017
CommunYang A, Yu
disease treated with radioiodine
Alonso GT, Rabon S, Weight gain after treatment of Clin
2017
White
Graves' disease in children.
Endocrinol
Viola D, Giani C,
Mazzeo S, Ugolini C, KIF5B/RET Rearrangement in a
J ClinCiampi R, Molinaro E, Carcinoma of the Thyroid
Endocrinol 2017
Agate L, Borrelli N, Gland: A Case Report of a Fatal
Metab
Chella A, Fontanini G, Disease.
Basolo F, Elisei

108(2)

21(2)231-239

60(1)

9-15

71(3)

159-6784(3)408-1612(1)e167-738

57-67

161(1)

127-133

35(23)

2692-2699

31(1)

71-83

102(9)

3091-3096

Vagney M, Desquilbet
Survival times for cats with
L, Reyes-Gomez E,
hyperthyroidism treated with a
Delisle F,
J Feline
3.35 mCi iodine-131 dose: a2017
Devauchelle P,
Med Surg
retrospective study of 96
Rodriguez-Pineiro MI,
cases.
Rosenberg D, deAl Eyadeh AA, AlThyroid cancer post radioactive
Endokrynol
Sarihin KM, Etewi
iodine treatment for
2017
Pol
SM, Al-Omari AA,
hyperthyroidism (case series
Al-Asa'd RA, Haddad and review of the literature).
Giesecke P,
Increased Cardiovascular
Rosenqvist M,
Mortality and Morbidity in
Frykman V, Friberg L, Patients Treated for Toxic
Thyroid
2017
Wallin G, Hoijer J,
Nodular Goiter Compared toLonn S, Torring
Graves' Disease and Nontoxic
Postoperative radioactive
Zhang H, Cai Y,
iodine-131 ablation is not
Hell J Nucl
2017
Zheng L, Zhang Z,
necessary among patients with Med
Jiang
intermediate-risk differentiated
Scerrino G, Melfa G,
Raspanti C, Attard A,
The prevalence of postMazzola S, Gullo R,
Langenbeck
thyroidectomy chronic asthenia:
2017
Bonventre S, Attards Arch Surga prospective cohort study.
M, Cocorullo G,
Gulotta
Cebulska-Wasilewska Retrospective Biological
A, Krzysiek M,
Dosimetry at Low and HighGenome2017
Krajewska G, Stepien Doses of Radiation andIntegrA, Krajewski
Radioiodine Impact on Individual
Al-Qurayshi Z,
Minimal extrathyroidal
EndocrShama MA, Randolph extension does not affect
Relat
2017
GW, Kandilsurvival of well-differentiated
CancerLucy JM, Peterson
Efficacy of Low-dose (2ME, Randolph JF,
millicurie) versus StandardScrivani PV, Rishniw
J Vet Interndose (4 millicurie) Radioiodine
2017
M, Davignon DL,
Med
Treatment for Cats with MildThompson MS,
to-Moderate Hyperthyroidism.
Scarlett
Kim J, Cho SG, Kang Preparation for radioactive
Medicine
SR, Kwon SY, Choiodine therapy is not a risk
2017
(Baltimore)
DH, Cho JS, Songfactor for the development ofJeong JH, Kong EJ, Clinical outcomes of low-doseJeong SY, Lee SW, and high-dose postoperative
Nucl Med2017
Cho IH, Ah Chun K, radioiodine therapy in patients Commun
Lee J, Ahn
with intermediate-risk
Deandreis D, Rubino Comparison of Empiric Versus
C, Tala H, Leboulleux Whole-Body/-Blood Clearance
S, Terroir M, Baudin Dosimetry-Based Approach to
J Nucl Med 2017
E, Larson S, Fagin
Radioactive Iodine Treatment in
JA, Schlumberger M, Patients with Metastases from
TuttleDifferentiated Thyroid Cancer.
Parameswaran R,
Patterns of metastasis in
Ann R Coll
Shulin Hu J, Min En follicular thyroid carcinoma and2017
Surg Engl
N, Tan WB, Yuan
the difference between early
Sabet A, Binse I,Distinguishing synchronous
Dogan S, Koch A,
from metachronous
Eur J Nucl
Rosenbaum-Krumme manifestation of distant
Med Mol
2017
SJ, Biersack HJ,
metastases: a prognostic
Imaging
Biermann K, Ezziddin feature in differentiated thyroid

1098612X17718416

27(7)878-885

20(1)

3-10

402(7)

1095-1102

8

2

24(5)

221-22631(2)326-334

96(5)

e6004

38(3)

228-23358(5)717-72299(2)151-15444(2)190-195

52040

76-7

47-9

990

58344-5361-2